08:00 , Feb 10, 2011 |  BC Innovations  |  Tools & Techniques

Models for QT prolongation

A group at the Technion Israel Institute of Technology and a team at the Stanford University School of Medicine...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Clinical News

MEM 1003: Phase IIa data

In a double-blind, U.S. Phase IIa trial in 183 patients, MEM 1003 missed the primary endpoint of a significant improvement in ADAS-cog score vs. placebo after 12 weeks. The company said there was a high...
07:00 , Oct 22, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
01:55 , Oct 16, 2007 |  BC Extra  |  Clinical News

Memory off after AD data

MEMY fell $0.69 (39%) to $1.06 on Monday after MEM 1003 missed the primary endpoint of a significant improvement in Alzheimer's Disease Assessment Scale--Cognitive subscale (ADAS-cog) score vs. placebo after 12 weeks in a Phase...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Clinical News

MEM 1003: Completed Phase IIa enrollment

MEMY completed enrollment in a double-blind, U.S. Phase IIa trial in 180 patients. The trial will compare 30 or 90 mg of twice-daily MEM 1003 to placebo after 12 weeks. Patients will then be evaluated...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Clinical News

MEM 1003: Phase IIa data

In a double-blind, placebo-controlled Phase IIa trial in 84 patients, MEM 1003 missed all primary and secondary endpoints. MEMY said 26% of patients receiving MEM 1003 showed a 50% improvement from baseline in YMRS vs....
01:20 , Mar 6, 2007 |  BC Extra  |  Clinical News

Memory falls on acute mania data

MEMY fell $1.12 (36%) to $2.01 on 1.7 million shares on Monday after MEM 1003 missed the primary and secondary endpoints in a Phase IIa trial to treat acute mania in bipolar disorder. In the...
08:00 , Mar 5, 2007 |  BC Week In Review  |  Company News

Memory Pharmaceuticals, The Stanley Medical Research Institute deal

MEMY received a $640,000 milestone from the institute in January under a 2006 deal to develop MEMY's MEM 1003 to treat acute mania in bipolar disorder. The payment was triggered by MEMY meeting a set...
08:00 , Feb 26, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
08:00 , Jan 22, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...